G

ood morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and invigorating, because that predictable and demanding routine of deadlines and meetings has returned. You knew this was inevitable, yes? Well, to cope, perhaps you would like to join us for a cup of stimulation to fortify those nerve endings. Remember that no prescription is required. We are opting for vanilla macadamia nut, by the way. So time to get started. Here are some items of interest. Hope your day goes well and do stay in touch …

A GlaxoSmithKline (GSK) gene therapy for “bubble boy” disease was approved by the U.K.’s cost watchdog, despite a $700,000 price tag, The Telegraph tells us. The Strimvelis treatment is offered by only one hospital in the world, in Italy, and children will be flown to Milan for a one-off cure. The medicine improves overall survival compared with standard stem cell transplant therapy against adenosine deaminase deficiency, which is an inherited condition.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.